MedPath

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

Conditions
Amyotrophic Lateral Sclerosis
Registration Number
NCT06069934
Lead Sponsor
Prilenia
Brief Summary

Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials.

Detailed Description

ALS: Pridopidine will be given at a dose of 45 mg twice daily p.o. (or via feeding tube) over a 2-week up-titration period; followed by pridopidine 45 mg twice daily p.o. (or via feeding tube) for the remainder of the treatment period (through Week 104).

Each patient will be followed for 2 years with regularly scheduled visits. The screening and baseline visits will be performed in person; subsequent visits may occur in person or remotely. Recommended in-person visits will occur at Weeks 12, 52, 78, and end of treatment (Week 104 or early termination). If the patient is unable to complete the visits in person, these visits may also be completed remotely.

Recruitment & Eligibility

Status
NO_LONGER_AVAILABLE
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (32)

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Barrow Neurological Institute

🇺🇸

Phoenix, Arizona, United States

University of California, San Diego Health

🇺🇸

La Jolla, California, United States

UC Irvine

🇺🇸

Orange, California, United States

California Pacific Medical Center - Forbes Norris MDA/ALS Research Center

🇺🇸

San Francisco, California, United States

University of Colorado Anschutz Medical Campus

🇺🇸

Aurora, Colorado, United States

Hospital for Special Care

🇺🇸

New Britain, Connecticut, United States

Nova Southeastern University

🇺🇸

Fort Lauderdale, Florida, United States

Mayo Clinic Jacksonville

🇺🇸

Jacksonville, Florida, United States

University of South Florida

🇺🇸

Tampa, Florida, United States

Scroll for more (22 remaining)
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.